NCT05329623View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

April 7, 2024

Study Completion Date

April 7, 2024

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

JDQ443

All the participants will receive a single oral dose of JDQ443.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

78215

Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY